
Kathleen N Moore MD
Gynecologic Oncology, Hospice & Palliative Medicine
Assistant Professor, Obstetrics & Gynecology, University of Oklahoma
Join to View Full Profile
825 NE 10th StOupb5200Oklahoma City, OK 73104
Phone+1 405-271-7770
Are you Dr. Moore?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Kathleen Moore, MD is an obstetrician/gynecologist in Oklahoma City, Oklahoma. She is currently licensed to practice medicine in Oklahoma, Pennsylvania, and Pennsylvania. She is affiliated with OU Health and is an Assistant Professor at University of Oklahoma.
Education & Training
- UPMC Medical EducationResidency, Obstetrics and Gynecology, 2000 - 2004
- University of Washington School of MedicineClass of 2000
Certifications & Licensure
- OK State Medical License 2004 - 2026
- PA State Medical License 2001 - 2004
- PA State Medical License 2001 - 2004
- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Publications & Presentations
PubMed
- State of the art endocrine treatments for patients diagnosed with endometrial cancer in 2025.Fernanda B Musa, Kathleen N Moore, Vivek Podder, Brian M Slomovitz
Current Opinion in Obstetrics & Gynecology. 2025-04-01 - Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II...Shailender Bhatia, Suzanne L Topalian, William Sharfman, Tim Meyer, Neil Steven
Journal of Clinical Oncology. 2025-03-20 - Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update.Stéphanie Gaillard, Christina Lacchetti, Deborah K Armstrong, William A Cliby, Mitchell I Edelson
Journal of Clinical Oncology. 2025-03-01
Press Mentions
- Ovarian Cancer Highlights from ESGO 2025March 14th, 2025
- Durvalumab plus Carboplatin and Paclitaxel Delivers One-Two Punch for Endometrial Cancer TreatmentMarch 14th, 2025
- Five OU Researchers Among Top 1% Most Highly Cited WorldwideJanuary 13th, 2025
- Join now to see all